Cyclosporine in ulcerative colitis flares;Ciclosporina en el brote grave de colitis ulcerosa

Gastroenterologia y Hepatologia

Volumn 28, Issue 10, 2005, Pages 629-631

  Nos, P ^a   Hinojosa, J ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL DE SAGUNTO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A;

COLONOSCOPY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; HUMAN; PROGNOSIS; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 30944470207     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5705(05)71528-4     Document Type: Editorial

References (16)

1. Blomberg B, Jarnerot G. Clinical evaluation and management of acute severe colitis. Inflamm Bowel Dis. 2000;6:214-27.
2. García-López S, Gomollón-García F, Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005;28:607-14
3. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-31.
4. Humbert H. Variability of the bioavailability of cyclosporine: benefit of the Neoral. Therapie. 1997;52:353-7.
5. Molnár T, Szepes Z, Nagy F, Lonovics J. Oral cyclosporine rescue therapy in severe, steroid refracgtory ulcerative colitis. Gut. 2003;52:A210.
6. Molnar T, Szepes Z, Nagy F, Szenohradszki P, Lonovics J. Open questions concerning cyclosporine therapy in ulcerative colitis. Gastroenterology. 2004;126:1495-6.
7. Van Assche G, Rutgeerts P. Reply. Gastroenterology. 2004; 126:1496.
8. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-10.
9. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-87.
10. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273-9.
11. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28:365-73.
12. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339-46.
13. Domènech E, García-Planella E, Bernal I, Rosinach M, Cabré E, Fluvia L, et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2002;16:2061-5.
14. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:1-16.
15. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;25(1):CD004277.
16. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo controlled study. Gastroenterology. 2005;128:1805-11.